Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHING-ID fractional-dose shingles vaccination study
2026-526934-16-00Phase 3Authorised
- Sponsor
- Leiden University Medical Center
- Start
- Oct 2026
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of Zoster vaccine recombinant in herpes zoster (HZ), sponsored by Leiden University Medical Center. Primary endpoint: Geometric mean concentration of anti-gE varicella zoster virus antibodies at Day 90. Planned start Oct 2026; status: authorised.
02
Drugs
Zoster vaccine recombinant
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on 2026-526934-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526934-16-00.